Tweets by IDWeek 2023

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

395 Views

047. COVID-19: Treatment: Thursday, 12:15 - 1:30 p.m.

Poster Session: COVID-19: Treatment

(522) Real-World, Retrospective Descriptive Study of COVID-19 Outpatient Therapeutic Uptake in High-Risk Patients Subsequently Hospitalized for COVID-19 During the Omicron Period in the US

Thursday, October 12, 2023

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Co-Author(s)

AS

Amie Scott, MPH

Director, Hospital Real-World Evidence Scientist
Pfizer, Inc
New York, New York, United States
LP

Laura A. Puzniak, PhD. MPH

Pfizer Inc.
Collegeville, Pennsylvania, United States
MM

Michael V. Murphy, BA

Principal Scientist
Genesis Research
Hoboken, New Jersey, United States
DB

Darrin W. Benjumea, MPH

Director
Genesis Research, LLC
Hoboken, New Jersey, United States
AR

Andrew Rava, MPH

Genesis Research
Hoboken, New Jersey, United States
MB

Michael Benigno, MA

Senior Director - Real World Evidence Lead for Hospital Business Unit
Pfizer, Inc
New York, NY, United States
KA

Kristen E. Allen, MPH

Pfizer, Inc.
Minneapolis, Minnesota, United States
RS

Richard Stanford, PharmD, MS

VP, Strategic Consulting
AESARA
Chapel Hill, North Carolina, United States
FM

Fadi Manuel, PharmD

AESARA
Chapel Hill, North Carolina, United States
Ashley S. Cha-Silva, PharmD, MS (she/her/hers)

Director
Pfizer
New York, New York, United States
LJ

Lili Jiang, PhD, MPH, MSc

Pfizer
Collegeville, Pennsylvania, United States
MR

Maya Reimbaeva, MS

Sr Manager Stats Program
Pfizer, Inc.
Groton, Connecticut, United States

Florin Draica, MD (he/him/his)

Senior Medical Director, HQ PAXLOVID Team Lead
Pfizer, Inc.
New York, New York, United States